NCT02633111 - DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas | Biotech Hunter

Enrollment

501

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

B-cell Non-Hodgkin LymphomaAggressive

Interventions

OTHER

collected at pre-treatment tumor biopsy

to identify the tumor-specific clonotype

OTHER

Peripheral blood tests

for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).

DEVICE

PET/CT

at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)

Trial Locations (12)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Cancer Center, Harrison

Memorial Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Nassau, Uniondale

Memorial Sloan Kettering Commack, Commack

Mayo Clinic, Rochester

Md Anderson Cancer Center, Houston

University of Miami, Miami

Memorial Sloan Kettering Basking Ridge, Basking Ridge

Memorial Sloan Kettering Monmouth, Middletown

Memorial Sloan Kettering Bergen, Montvale

University of Pennsylvania, Philadelphia